The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

In a new report, global health experts are urging that we redefine the measurements used to determine whether someone is ...

More than 90 per cent of weight loss jab users are forced to pay for treatment privately due to their slow roll-out on the ...

Viral TikTok alternatives like Natural Mounjaro, Oatzempic, and Tadpole water claim to aid weight loss by curbing appetite ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

Weight loss drugs are seen as an easy option for dropping the pounds, but they are also expensive, and can have nasty side ...